atorvastatin has been researched along with ritonavir in 18 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (11.11) | 18.2507 |
| 2000's | 8 (44.44) | 29.6817 |
| 2010's | 8 (44.44) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Honda, K; Izumi, T; Miyaji, Y; Nakayama, S; Okazaki, O; Okudaira, N; Shiosakai, K; Sugiyama, D; Suzuki, W; Takakusa, H; Watanabe, A | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Barton, P; Ismair, M; Jupp, R; Riley, RJ; Soars, MG | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Henry, K; Hermundson, J; Huebesch, J; Melroe, H; Simpson, J | 1 |
| Martín, T; Murillas, J; Portero, JL; Ramos, A | 1 |
| Aberg, JA; Alston, B; Aweeka, F; Blaschke, T; Fang, F; Fichtenbaum, CJ; Gerber, JG; Kosel, B; Rosenkranz, SL; Segal, Y | 1 |
| Piliero, PJ | 1 |
| Gill, MJ; Mah Ming, JB | 1 |
| Hochman, JH; Lin, JH; Prueksaritanont, T; Pudvah, N; Qiu, J; Tang, C; Yamazaki, M | 1 |
| Hirsch, RL | 1 |
| Gaughan, JP; Klibanov, OM; Tedaldi, EM; van den Berg-Wolf, M | 1 |
| Barditch-Crovo, P; Cameron, DW; Elgadi, MM; Flexner, C; Fuchs, E; la Porte, CJ; Lee, LS; Pham, PA; Piliero, PJ; Sabo, JP; van Heeswijk, R | 1 |
| de Serres, M; Gould, E; Johnson, M; Kim, J; Lou, Y; Mayers, D; Pietropaolo, K; Piscitelli, S; White, S; Zhou, XJ | 1 |
| Also, MA; Bastida, C; Letang, E; Miró, JM; Pericas, JM; Tuset, M | 1 |
| Sungkanuparph, S; Wangpatharawanit, P | 1 |
1 review(s) available for atorvastatin and ritonavir
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
4 trial(s) available for atorvastatin and ritonavir
| Article | Year |
|---|---|
Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047.
Topics: Adult; Anticholesteremic Agents; Atorvastatin; Drug Interactions; Heptanoic Acids; HIV Protease Inhibitors; HIV Seronegativity; Human Experimentation; Humans; Pravastatin; Pyrroles; Ritonavir; Saquinavir; Simvastatin | 2002 |
Differential effects of tipranavir plus ritonavir on atorvastatin or rosuvastatin pharmacokinetics in healthy volunteers.
Topics: Adolescent; Adult; Aged; Anti-HIV Agents; Atorvastatin; Drug Interactions; Female; Fluorobenzenes; Heptanoic Acids; Humans; Male; Middle Aged; Pyridines; Pyrimidines; Pyrones; Pyrroles; Ritonavir; Rosuvastatin Calcium; Sulfonamides; Young Adult | 2009 |
Drug interaction profile for GSK2248761, a next generation non-nucleoside reverse transcriptase inhibitor.
Topics: Adenine; Androstenes; Anti-HIV Agents; Atazanavir Sulfate; Atorvastatin; Contraceptives, Oral; Cross-Over Studies; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Darunavir; Deoxycytidine; Double-Blind Method; Drug Combinations; Drug Interactions; Emtricitabine; Ethinyl Estradiol; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Least-Squares Analysis; Linear Models; Lopinavir; Male; Oligopeptides; Organophosphonates; Patient Safety; Phosphinic Acids; Pyridines; Pyrimidines; Pyrroles; Pyrrolidinones; Raltegravir Potassium; Reverse Transcriptase Inhibitors; Risk Assessment; Ritonavir; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Tenofovir | 2012 |
Switching Lopinavir/Ritonavir to Atazanavir/Ritonavir vs Adding Atorvastatin in HIV-Infected Patients Receiving Second-Line Antiretroviral Therapy With Hypercholesterolemia: A Randomized Controlled Trial.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Atorvastatin; Cholesterol; Female; HIV Infections; Humans; Hypercholesterolemia; Lipoproteins, LDL; Lopinavir; Male; Middle Aged; Ritonavir | 2016 |
13 other study(ies) available for atorvastatin and ritonavir
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.
Topics: Glutathione; Pharmacology; Sulfur Radioisotopes | 2011 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
The development, characterization, and application of an OATP1B1 inhibition assay in drug discovery.
Topics: Cell Line; Drug Discovery; Humans; Liver-Specific Organic Anion Transporter 1; Organic Anion Transporters | 2012 |
Atorvastatin and gemfibrozil for protease-inhibitor-related lipid abnormalities.
Topics: Anticholesteremic Agents; Atorvastatin; Drug Therapy, Combination; Gemfibrozil; Heptanoic Acids; Humans; Hyperlipoproteinemias; Hypolipidemic Agents; Protease Inhibitors; Pyrroles; Ritonavir; Saquinavir | 1998 |
Atorvastatin for protease inhibitor-related hyperlipidaemia.
Topics: Adult; Anticholesteremic Agents; Atorvastatin; Drug Therapy, Combination; Female; Heptanoic Acids; HIV Infections; HIV Protease Inhibitors; Humans; Hyperlipidemias; Male; Pyrroles; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir | 1999 |
Interaction between ritonavir and statins.
Topics: Atorvastatin; Cytochrome P-450 Enzyme System; Drug Interactions; Heptanoic Acids; HIV Protease Inhibitors; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pravastatin; Pyrroles; Ritonavir; Simvastatin | 2002 |
Drug-induced rhabdomyolysis after concomitant use of clarithromycin, atorvastatin, and lopinavir/ritonavir in a patient with HIV.
Topics: Adult; Anti-Bacterial Agents; Atorvastatin; Clarithromycin; Drug Interactions; Drug Therapy, Combination; Heptanoic Acids; HIV Infections; HIV Protease Inhibitors; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lopinavir; Male; Pyrimidinones; Pyrroles; Rhabdomyolysis; Ritonavir | 2003 |
Interactions of human P-glycoprotein with simvastatin, simvastatin acid, and atorvastatin.
Topics: Atorvastatin; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport, Active; Cell Line; Drug Interactions; Heptanoic Acids; Humans; Hypolipidemic Agents; Pyrroles; Ritonavir; Simvastatin; Time Factors | 2004 |
Torcetrapib and atorvastatin.
Topics: Atorvastatin; Drug Costs; Drug Industry; Heptanoic Acids; HIV Protease Inhibitors; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Quinolines; Ritonavir | 2005 |
Ezetimibe combined with low-dose statin effectively lowers LDL in protease inhibitor treated patients.
Topics: Adult; Anticholesteremic Agents; Antiretroviral Therapy, Highly Active; Atorvastatin; Azetidines; Cholesterol, LDL; Drug Administration Schedule; Ezetimibe; Female; Follow-Up Studies; Heptanoic Acids; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Hypercholesterolemia; Lopinavir; Male; Middle Aged; Pilot Projects; Pravastatin; Prospective Studies; Pyrroles; Ritonavir; Treatment Outcome | 2008 |
[Rhabdomyolysis and severe hepatotoxicity due to a drug-drug interaction between ritonavir and simvastatin. Could we use the most cost-effective statin in all human immunodeficiency virus-infected patients?].
Topics: Antiretroviral Therapy, Highly Active; Atorvastatin; Chemical and Drug Induced Liver Injury; Comorbidity; Contraindications; Cost-Benefit Analysis; Cytochrome P-450 CYP3A Inhibitors; Drug Substitution; Drug Synergism; Dyslipidemias; Female; HIV Infections; HIV Protease Inhibitors; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Tubular Necrosis, Acute; Middle Aged; Rhabdomyolysis; Ritonavir; Simvastatin | 2014 |